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Abstract Antibodies are important tools for experimental
research and medical applications. Most antibodies are com-
posed of two heavy and two light chains. Both chains con-
tribute to the antigen-binding site which is usually Xat or
concave. In addition to these conventional antibodies, llamas,
other camelids, and sharks also produce antibodies composed
only of heavy chains. The antigen-binding site of these
unusual heavy chain antibodies (hcAbs) is formed only by a
single domain, designated VHH in camelid hcAbs and
VNAR in shark hcAbs. VHH and VNAR are easily produced
as recombinant proteins, designated single domain antibodies
(sdAbs) or nanobodies. The CDR3 region of these sdAbs
possesses the extraordinary capacity to form long Wngerlike
extensions that can extend into cavities on antigens, e.g., the
active site crevice of enzymes. Other advantageous features
of nanobodies include their small size, high solubility, ther-
mal stability, refolding capacity, and good tissue penetration
in vivo. Here we review the results of several recent proof-
of-principle studies that open the exciting perspective of
using sdAbs for modulating immune functions and for target-
ing toxins and microbes.
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Abbreviations
CDR Complementarity determining region
FR Framework region
hcAb Heavy chain antibody
sdAb Single domain antibody
VHH Variable domain of camelid heavy chain antibody
VNAR Variable domain of the shark new antigen receptor
Introduction
The vertebrate immune system generates billions of diVer-
ent antibody molecules. This enormous repertoire contains
highly speciWc binding partners for practically every exist-
ing biological and chemical compound. Following immuni-
zation, B-cells that express a suitable antibody expand a
million-fold by clonal proliferation in lymphatic organs.
Well orchestrated mutation and selection mechanisms
ensure the preferential expansion of variants that express
antibodies with higher aYnity to the immunogen. Repeated
immunization, thus, generally yields higher quantities and
higher aYnities of speciWc antibodies. Hybridoma and genetic
engineering technologies can be used to harness and to
reformat individual antibodies obtained from immunized
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Med Microbiol Immunolanimals and even to reconstruct recombinant molecules
semi-synthetically. Today, monoclonal antibodies and anti-
body-derived recombinant proteins are essential tools for
experimental research and medical applications [1].
The peculiar structure and biochemical features of camelid 
and shark hcAbs
Most antibodies are composed of two heavy and two light
chains (Fig. 1). Both chains contribute to the two identical
antigen-binding sites, which are usually Xat or concave. In
addition to these conventional antibodies, camelids and
sharks also produce unusual antibodies composed only of
heavy chains (Fig. 1) [2, 3]. These peculiar heavy chain
antibodies (hcAbs) lack light chains (and, in the case of
camelid antibodies, also the CH1-domain). Therefore, the
antigen-binding site of hcAbs is formed only by a single
domain that is linked directly via a hinge region to the
Fc-domain. The variable domain is designated VHH for cam-
elid hcAbs (Fig. 2) and VNAR for shark hcAbs, and more
generally, nanobody or single domain antibody (sdAb) [4].
The CDR3 region of these hcAbs possesses the extraor-
dinary capacity to form long Wngerlike extensions that can
extend into cavities on antigens, e.g., the active site crevice
of enzymes. Figure 3 illustrates this unique antigen–anti-
body interaction in crystal structures of hen egg lysozyme
in complex with an sdAb from shark (a) and camel (b). The
CDR3 of these sdAbs can form convex extensions that
occupy the cleft for the substrate (Fig. 3c). In contrast, the
Fab-fragment derived from a conventional mouse monoclo-
nal antibody binds with a relatively Xat interaction face,
well outside the active site (Fig. 3d) [5]. Indeed, the
immune system of camelids seems to possess an inherent
propensity for forming enzyme-blocking hcAbs [6].
The CDR3 of VHHs and VNARs is often much longer
than that of conventional VH domains, e.g., 24 and 18 resi-
dues in case of the illustrated anti-lysozyme sdAbs versus 7
residues in the mouse VH (Fig. 4) [7, 8]. The extended
CDR3 is often, but not always, stabilized by an additional
disulWde bond connecting the CDR3 to the adjacent CDR1
loop (common in camel and shark sdAbs) or to the CDR2
loop (common in llama sdAbs) (Figs. 2 and 4). The interface
of conventional VH and VL domains is stabilized by hydro-
phobic interactions, the corresponding residues in llama anti-
bodies are replaced by hydrophilic residues (pink region in
Fig. 1 and pink residues in Fig. 4). In shark sdAbs, the CDR2
loop is replaced by two shorter less variable loops (Fig. 4).
Fig. 1 Distinguishing structural features of camelid and shark hcAbs.
Conventional Abs composed of heavy (H) and light (L) chains are
found in all vertebrates. Heavy chain antibodies are found in camelids
and sharks. Immunoglobulin domains are depicted as ellipsoid
domains. Interchain disulWde bonds are indicated by black lines,
glycosylation sites as hexagons. The antigen-binding paratope (P) of
conventional Abs is formed by the variable domains of heavy and light
chains (VH and VL), while the paratope of heavy chain Abs is formed
only by the heavy chain variable domain, which is designated VHH in
camelid hcAbs and VNAR in shark IgNARs. VH and VL domains in
conventional Abs display hydrophobic binding interactions, while the
corresponding region in hcAbs is hydrophilic (depicted in pink). Note
that in camelid hcAbs the V-domains are directly connected to the
hinge region, owing to the lack of the CH1 domain. Camelid hcAbs
come in two variants, distinguished on the basis of the lengths of their
hinge region and designated as long- and short-hinge isotypes (as
depicted schematically in the diagrams)
Fig. 2 Schematic diagram of the VHH domain of a camelid heavy
chain antibody. a The three complementarity determining regions
(CDRs) of the antigen-binding paratope are depicted as colored loops:
CDR1 red, CDR2 green, and CDR3 blue. b The canonical disulWde
bond connecting framework regions 1 and 3 (FR1 and FR3) in the two
b-sheets of the immunoglobulin domain is indicated in yellow. Many
camelid antibodies contain an additional disulWde bond (S–S) connect-
ing the CDR3 with the end of the CDR1 (camels) or the beginning of
the CDR2 (llamas). h Hinge, M transmembrane domain of membrane
isoform, G glycosylation site, S stop codon of secretory isoform123
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sdAbs
sdAbs are usually generated by PCR cloning of the V-domain
repertoire from blood, lymph node, or spleen cDNA
obtained from immunized animals into a phage display
vector, such as pHEN2 (Fig. 5). Antigen-speciWc sdAbs are
commonly selected by panning phage libraries on immobi-
lized antigen, e.g., antigen coated onto the plastic surface of
a test tube, biotinylated antigens immobilized on Streptavi-
din beads, or membrane proteins expressed on the surface
of cells. Several labs have also constructed semi-synthetic
libraries by cassette-mutagenesis of the CDR regions. The
latter oVers the advantage of selecting antibodies against
toxic or diYcult to express antigens. However, sdAbs
derived from such non-immune libraries often show lower
aYnities for their antigen than sdAbs derived from animals
that have received several immunizations [8–10]. The high
aYnity of sdAbs from immune libraries is attributed to the
natural selection of variant sdAbs during clonal expansion
of B-cells in the lymphoid organs of the immunized ani-
mals. The aYnity of sdAbs from non-immune libraries can
often be improved by mimicking this strategy in vitro, i.e.,
by site directed mutagenesis of the CDR regions and further
rounds of panning on immobilized antigen under conditions
of increased stringency (higher temperature, high or low
salt concentration, high or low pH, and low antigen concen-
trations).
sdAbs derived from camelid and shark hcAbs are readily
expressed in and puriWed from the E. coli periplasm at
much higher expression levels than the corresponding
domains of conventional antibodies (Fig. 6). sdAbs gener-
ally display high solubility and stability and can also be
readily produced in yeast, plant, and mammalian cells [8].
Recombinantly expressed sdAbs display several advan-
tages as compared to conventional antibodies and the single
chain variable fragments (scFv) derived from the
V-domains of conventional antibodies. Their high thermal
stability, high refolding capacity, and good tissue penetration
in vivo [3, 11, 12] make nanobodies ideally suited for vari-
ous biotechnological and therapeutic applications. More-
over, sdAbs can be readily cloned into various formats by
fusion to other proteins or peptides, thereby tailoring their
utility for certain diagnostic and/or therapeutic applications
(Fig. 7) [13]. For example, fusion to a Xuorescent protein
yields a Xuorescent probe (also designated chromobody or
Fig. 3 3D-structures of enzyme-inhibiting sdAbs derived from camel
and shark hcAbs. Images were generated with the PyMOL program
[123]. The three CDR loops are color-coded as in Fig. 2: CDR1 red,
CDR2 green, CDR3 blue, and disulWde bonds are depicted in yellow.
a Chicken lysozyme in complex with an inhibitory shark sdAb VNAR
(pdb code 1t6v). The VNAR contacts the enzyme only with its CDR1
and CDR3 regions, the latter extends into and blocks the active site cre-
vice [124]. b Chicken lysozyme in complex with an inhibitory camel
sdAb (pdb code 1mel). The CDR3 extends into and Wlls out the active
site crevice of the enzyme [5]. c Chicken lysozyme in complex with its
substrate (pdb code 1lsz) [125]. d Chicken lysozyme in complex with
the VL and VH domains of a conventional mouse mAb (pdb code
1mlc). The Xat interaction surface with the conventional antibody lies
outside of the active site crevice [126]
Fig. 4 Amino-acid sequence alignment of heavy chain variable
domains of conventional (VH), camelid (VHH), and shark (VNAR)
antibodies. Amino acids are color-coded as in previous Wgures: CDR1
red, CDR2 green, CDR3 blue, hydrophilic motif in FR2 pink, and cysteine
residues yellow. The sequences are derived from the anti-lysozyme VH
(mAbVH), VHH (cAbLys3), and VNAR domains shown in Fig. 3a, b,
and d. VHH s+16a is an enzyme-blocking sdAb derived from a llama
immunized with the murine T-cell ecto-enzyme ART2.2 [29]123
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[14, 15]. Tandem cloning of two identical sdAbs connected
by a linker peptide yields a bivalent reagent with higher
avidity for the antigen [13]. Tandem cloning to an sdAb
with a distinct speciWcity, e.g., for serum albumin, can help
target the reagent to a particular compartment and/or help
to increase the in vivo half life of the reagent [16]. A biva-
lent hcAb can be reconstituted by genetic fusion to the
Fc-domain of any conventional antibody, e.g., mouse or
human IgG1. Fusion to a cell surface protein, e.g., of lacto-
bacillus, a commensal gut bacterium, yields a reagent des-
ignated lactobody with a massively increased binding
surface for the antigen of interest, e.g., rotavirus, the etio-
logical agent of severe diarrhea in children [17]. Owing to
their high stability and excellent folding capacity under
diVerent environmental conditions, sdAbs have also been
targeted successfully to the cytosol by removing the leader
peptide [18] and to intracellular vesicles, such as chloro-
plasts [19] or the endoplasmic reticulum [20] by genetic
fusion to suitable targeting sequences.
Single domain antibodies in immunity
The remarkable success of conventional TNF-a neutraliz-
ing antibodies in the therapy of rheumatoid arthritis and
other inXammatory diseases [21] have fueled the quest for
other antibody-based therapeutic tools. Many new anti-
body-based reagents have hence been licensed for the treat-
ment of auto-immune diseases and allergies, as well as for
the immune therapy of cancers [22]. For example, B-cell
depletion mediated by an antibody against CD20 (Ritux-
imab/Rituxan) shows beneWcial eVects in rheumatoid
arthritis, systemic lupus erythematosus, and other autoim-
mune diseases, an antibody against IgE has been approved
for the therapy of severe asthma (Omalizumab/Xolair), and
antibodies against the epidermal growth factor receptors
ErbB-1 and ErbB-2 (Cetuximab/Erbitux and Trastuzumab/
Herceptin) for the therapy of colorectal and breast cancers.
The very high cost of conventional antibodies is already
becoming a major burden for the health care budgets in
many countries [23]. Roche, for example, has invested sev-
eral hundred million Euros for a new production facility
Fig. 5 Schematic diagram of the M13 phage display vector used for
cloning libraries of the VHH and VNAR repertoires of immunized
camelids and sharks. The open reading frame of the V-domains from
hcAbs are PCR ampliWed from cDNA generated from lymphocytes
puriWed from peripheral blood, lymph node, or spleen cDNA of an
immunized animal, typically obtained 4–14 days after the Wnal boost.
The puriWed PCR ampliWcation products are cloned into the phagemid
vector downstream of an inducible bacterial promoter (arrow),
in-frame behind a periplasm signal sequence (BL = bacterial leader
peptide) and upstream of one or two epitope tags (T), an amber stop
codon followed by the coding sequence of the M13 phage head capsid
protein gIIIp. The phagemids are transfected into an E. coli strain that
can read through the amber stop codon. Following infection with a
helper phage, libraries of recombinant phage particles are harvested
from bacterial culture supernatants and phages displaying sdAbs of
interest are selected by panning on immobilized antigen. Bound phages
are subjected to one or more additional rounds of selection. Phagemids
are recuperated from single colonies of infected E. coli and the cDNA
insert subjected to sequencing
Fig. 6 Expression and puriWcation of sdAbs. Single domain antibod-
ies carrying C-terminal epitope tags are readily generated following
transfection of the phagemids into an E. coli strain that recognizes the
amber stop codon. sdAbs can be puriWed from periplasmic lysates by
aYnity chromatography, e.g., on immobilized nickel ions, as illus-
trated in this Coomassie stain of a llama VHH (lanes 3 and 4) and of a
shark VNAR (lanes 7 and 8) directed against the lymphocyte ecto-
enzyme CD38. Periplasmic lysates obtained from the cell pellets of
100 ml E. coli cultures were subjected to aYnity chromatography on
1 ml Ni-NTA columns. Aliquots of protein suspensions obtained dur-
ing puriWcation were size fractionated by SDS-PAGE and stained with
Coomassie. Lanes 1 and 5: total proteins in periplasmic lysates as loaded
onto the column, lanes 2 and 6: column Xow through, lanes 3–4 and
7–8 proteins eluted from the Ni-NTA column by imidazole. The pro-
tein yield from the 100 ml E. coli culture was 0.5–1 mg of sdAb.
M = molecular weight markers, size indicated in kilodalton (kD)123
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body (Trastuzumab) and a similar facility (Building 95 in
Basel) for the production of Bevacizumab (anti-VEGF).
Owing to their smaller size and ease of production, sdAbs
present an interesting alternative to conventional antibodies
for immune therapy. Potential targets include cell surface
proteins, cytokines, other secreted proteins, and even intra-
cellular proteins (Table 1).
Targeting leukocyte ecto-enzymes
Leukocytes express numerous ecto-enzymes that have their
active sites exposed to the extracellular environment. These
enzymes play important roles in cell traYcking, inXamma-
tion, and apoptosis [24, 25]. For example, NAD-dependent
ADP-ribosyltransferases (ARTs, also named CD296)
regulate the function of other cell surface proteins by post-
translational modiWcation [26, 27]. Other nucleotide-
metabolizing ecto-enzymes (CD38, CD39, CD73, CD157,
and CD203) control the half-life of purinoreceptor-ligands
and/or generate signaling molecules, such as cyclic ADP-
ribose, adenosine, and lysophosphatidic acid [28]. Pepti-
dases (CD10, CD13, CD26, CD156, and CD249) control
the shedding and processing of cytokines and cell adhesion
molecules. Given the important regulatory functions of
these enzymes, speciWc inhibitors of their activities might
be useful as tools to modulate immune functions [25].
Small molecule inhibitors and antibodies oVer two possi-
ble strategies for inhibiting leukocyte ecto-enzymes [1, 25].
While small chemical antagonists often lack speciWcity,
antibodies have the capacity to discriminate between
closely related enzymes. As leukocyte cell surface ecto-
enzymes are accessible to antibodies, the remarkable pref-
erence of hcAbs for binding into the active sites of enzymes
oVers the possibility to raise selective enzyme-blocking
sdAb-reagents [5, 6]. The crystal structures of several leu-
kocyte ecto-enzymes have been elucidated, and in many
cases they display a deep active site crevice that may be
suitable for targeting by sdAbs (Fig. 8a, b).
In a recent proof-of-principle study, we have generated
sdAbs against the toxin-related murine T-cell ecto-ADP-
ribosyltransferase ART2.2 (Table 1; Fig. 7a) [29]. This cell
surface enzyme plays an important regulatory role in
inXammatory settings, where it senses NAD released from
damaged cells [30–32]. ART2.2 mediates NAD-induced
cell death of naive T-cells by ADP-ribosylating the cyto-
lytic P2X7 receptor [33, 34]. Three out of four distinct
ART2.2-speciWc VHHs isolated from an immune llama
phage display library were found to block the enzymatic
activity of ART2.2 [29]. Following intravenous injection, a
VHH (s+16a) was able to completely block ART2.2 enzy-
matic activity and NAD-induced cytotoxicity on the surface
Fig. 7 Schematic diagram of various formats of recombinant
sdAbs. a Monovalent sdAbs can be obtained directly from E. coli
transfected with phagemids selected as illustrated in Fig. 6. These
sdAbs can be used to block enzymes, such as T-cell ecto-ADP-
ribosyltransferase ART2.2, here symbolized by the Pacman [29].
b Monovalent sdAbs can be conjugated chemically to radioisotopes,
Xuorochromes, biotin, magnetic beads, aYnity matrices, etc. Radio-
labeled sdAbs can be used for in vivo imaging of tumors [43].
c Fusion of sdAbs to other proteins, such as green Xuorescent protein
(GFP) [127, 128] or the trypanolytic serum protein apolipoprotein
A [101] is accomplished by recloning of the PCR-ampliWed insert
into appropriate expression vectors. d Bivalent sdAbs are gener-
ated by tandem cloning of two V-domains separated by a Xexible
linker peptide of 12–20 amino acids [13]. e The same strategy can
be applied to fuse two distinct sdAbs, e.g., one encoding an albu-
min-speciWc sdAb, the other encoding a cytokine-speciWc sdAb
[16]. Inclusion of an albumin-speciWc sdAb results in a dramati-
cally increased in vivo half-life upon binding to albumin. f A biva-
lent hcAb format can be regenerated by fusion of the V-domain to
an IgG-Fc-domain [77]. The increased avidity is useful for diagnos-
tic purposes. Moreover, the hcAb format has a dramatically
increased serum half-life, which can be of great value for certain
therapeutic applications. g Fusion of an sdAb to a bacterial outer
membrane protein yields recombinant bacteria exposing hundreds
of copies of the sdAb on the cell surface, as in the illustrated exam-
ple of a rotavirus-speciWc VHH fused to an outer membrane prote-
ase of a commensal gut bacterium [17]. h Intracellular sdAbs are
generated by recloning the VHH (without the leader peptide) into a
eukaryotic expression vector. Transfection of cells with an SpvB-
speciWc sdAb protects cells from the cytotoxic action of the Salmo-
nella SpvB ADP-ribosyltransferase (here indicated by the
Pacman). Targeting to organelles can be achieved by fusion of
appropriate targeting sequences (not shown) [19, 20]. i sdAbs
directed against multimeric lumazine synthase (LS) can be used for
the construction of highly immunogenic molecular assembly vac-
cines. This could be used to enhance the antibody response against
an ADP-ribosyltransferase (here illustrated as a Pacman) fused to
an LS-speciWc sdAb. j sdAbs directed against the idiotype of a con-
ventional antibody can be used for molecular mimicry of the target
antigen [64]123
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blockade was eVective from within 10 min for at least 6 h
after injection. Subsequently, we constructed a chimeric
single domain antibody composed of VHH s+16a fused to
the Fc-domain of mouse IgG1 (Fig. 7f). Following i.v.
injection, these reconstituted chimeric hcAbs achieved
complete blockade of ART2.2 on lymph node cells within
2 h after injection. This somewhat slower inhibition than
sdAbs likely reXects the slower tissue penetration capacity
of the larger Fc-fusion protein. The blockade of ART2.2 by
s+16a-Fc was eVective for >7 days, reXecting the higher
in vivo half-life due to slower elimination via the kidney
and a high aYnity interaction with the anti-catabolic FcRn
molecule [35]. These antibodies provide unique tools to
speciWcally block the activity of a single member of the
ART-family of ecto-ADP-ribosyltransferases. Our ongoing
studies address the potential therapeutic utility of these
antibodies in autoimmune and other inXammatory diseases.
By analogy to ART2.2, other leukocyte ecto-enzymes
with deep active site crevices, such as CD38 (Fig. 8b),
CD39, CD203, and CD151 are potential therapeutic targets
[25]. With the goal of generating and cloning enzyme-
blocking sdAbs against these enzymes, we have initiated
immunizations of llamas and sharks with some of these
enzymes.
Targeting other cell surface proteins with sdAbs
Leukocytes and other cells express numerous other func-
tionally important membrane proteins that are not enzymes,
including receptors, ion channels and transporters.
Recently, nanobodies directed against the CD16 Fc-recep-
tor on natural killer (NK) cells were developed from an
immunized llama [36]. Once multimerized via biotin/Strep-
tavidin interactions, these sdAbs were capable of activating
NK cells, which makes them good candidates to be used in
bi-speciWc formats for recruiting NK cells to target and
destroy tumor cells. From a llama immunized with the
human A431 squamous cancer cell line, an sdAb speciWc
for the a3b1 integrin (VLA-3) was isolated that could
Table 1 Applications of sdAbs in immunity
Target Application Source of sdAb Reference
Membrane proteins
ART2.2 Blocking T-cell ecto-enzyme, 
treatment of auto-immune disease
Immune llama [29]
CD16 Activation of NK cells Immune llama [36]
a3b1 Integrin VLA-3 Block leukocyte-matrix adhesion Immune llama [37]
a 2,3 Sialoglyco-protein Crossing the blood brain barrier Non-immune llama [38, 39]
EGFR In vivo imaging, cancer immunotherapy Immune camel, immune llama [41–44, 110, 111]
CEA Cancer immunotherapy Immune llama [40]
MUC 1 Tumor targeting Immune camel and llama [45, 112]
CD105 (endoglin) Tumor targeting Immune camel [46]
Secretory proteins
TNFa Cytokine neutralization Immune llama and alpaca [16, 48, 113]
PSA Cancer diagnosis Immune dromedary [114, 115]
von Willebrand factor Blocking blood clotting Immune llama [50]
Amyloid Ab peptide Amyloid aggregation Immune dromedary and alpaca [53, 54]
Lysozyme Amyloidosis Immune dromedary [12, 52, 116]
IgG Depletion of auto-Abs Immune llama [55]
Serum albumin BispeciWc sdAbs, increase serum half-life Immune llama [16, 44]
Intracellular proteins
Bax Inhibiting apoptosis Non-immune llama [18]
HIF-1a Hypoxia response Non-immune llama [58, 59]
PABPN1 Aggregation disorders Immune and non-immune llama [60, 117, 118]
Vaccine enhancement
Lumazine synthase Molecular assembly vaccines Immune llama Urrutia, 
Danquah et al. 
(unpublished)
Molecular mimicry
Immunoglobulin idiotype Molecular mimicry Immune llama, non-immune shark [64, 65]123
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extracellular matrix [37].
In search of an agent that could be used to surmount the
blood brain barrier, a llama was immunized with brain vas-
cular endothelial cells [38]. One of the selected sdAbs,
directed against a 2-3 sialoglycoprotein, was found to
induce transcytosis of the sdAb through and release on the
basolateral side of endothelial cells [39]. In vivo studies
showed that this sdAb was eYciently transported across the
blood brain barrier and could even be used to carry geneti-
cally fused cargo into the brain, including the entire M13
phage particle [38].
Several sdAbs have been raised against receptors over-
expressed in tumors and/or tumor neovasculature with the
goal of generating tools for improving immune therapy of
tumors. Carcinoembryonic antigen (CEA, also named
CD66e) is highly expressed on cancer cells of epithelial ori-
gin, but not at all or only at low levels by adult cells.
A CEA-speciWc sdAb derived from an immunized dromedary
(cAb-CEA5) was fused to a b-lactamase, an enzyme that
can convert non-toxic prodrugs into potent cytotoxic agents
[40]. The fusion protein was found to localize preferentially
in tumors and to be cleared rapidly from the circulation via
the kidney. The combined treatment with sdAb-lactamase
fusion protein and an anticancer prodrug induced regres-
sions and cures of established tumor xenografts [40]. Sev-
eral groups have raised sdAbs against the epidermal growth
factor receptor (EGFR) [41–44]. Both, monovalent (17 kD)
and bivalent (35 kD) formats showed rapid tissue penetra-
tion as well as rapid clearance via the kidney. Conjugation
of monovalent sdAb to technetium-99 m (Fig. 7b), a short
lived gamma ray emitting isotope widely used in nuclear
medicine, permitted in vivo discrimination of EGFR
expressing tumors [43]. Tandem fusion of two anti-EGFR
VHHs with a VHH speciWc for serum albumin (Fig. 7e)
yielded a 50 kD single-chain reagent that also exhibited
excellent tissue penetration [44] with faster and deeper
tumor penetration than cetuximab, a conventional chimeric
monoclonal antibody currently used in the therapy of meta-
static colorectal cancer and squamous cell carcinoma of the
head and neck. Fusion to the albumin-speciWc sdAb
resulted in markedly enhanced serum half-life [44].
sdAbs recognizing mucin MUC1, an epithelial cell sur-
face protein over-expressed during lactation and in breast
cancer, and endoglin (CD105), an endothelial cell surface
protein associated with tumor neovascularization, were
isolated from immunized dromedaries and camels [45, 46],
yielding potential tumor targeting agents for cancer
therapy.
Targeting cytokines with sdAbs
In recent years, cytokine-neutralizing conventional anti-
bodies have revolutionized the therapy of rheumatoid
arthritis, psoriasis, and other chronic inXammatory dis-
eases [21, 47]. The great success of these antibodies has
prompted the quest for developing smaller, cytokine-neu-
tralizing sdAbs from camelids and sharks. TNF-a blocking
sdAbs have been isolated from a llama immunized with
human and mouse TNF-a [16] as well as from alpacas
immunized with ovine TNF-a [48]. Tandem fusion of two
human TNF-a speciWc VHHs (Fig. 7d) yielded bivalent
sdAbs with increased avidity and a more than 100-fold
increased TNF-a neutralizing activity [16]. These bivalent
sdAbs were markedly more eVective at neutralizing TNF-a
than the conventional TNF-a blocking antibodies inXix-
imab and adalimumab. Fusion to a third VHH speciWc for
serum albumin (Fig. 7e) yielded potent TNF-a neutralizing
sdAbs with enhanced serum half-life and enhanced target-
ing to inXamed joints in a mouse model of collagen
induced arthritis. Daily treatments initiated at the onset of
clinical symptoms signiWcantly reduced clinical severity.
These sdAbs are currently being developed for clinical
trials [49].
Fig. 8 3D-structures of leukocyte ecto-enzymes and toxin enzymes
with active site crevices targeted by sdAbs. a Murine T-cell ecto-ADP-
ribosyltransferase ART2.2 with substrate NAD (pdb code 1og3).
b Human lymphocyte ecto-NAD-glycohydrolase CD38 with substrate
NAD (pdb code 2i65). c Salmonella enterica virulence protein SpvB,
an actin ADP-ribosyltransferase, with NAD (pdb code 2gwl). d Clos-
tridium diYcile toxin B, a rho glucosyltransferase (pdb code 2bvl).
Images were generated with the PyMOL program [123]. We have
already generated enzyme-blocking sdAbs against ART2.2 and SpvB
from immunized llamas. Current work aims at generating similar anti-
bodies against CD38 and Toxin B from immunized llamas and sharks123
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Like cytokines, other secreted molecules that are func-
tionally important are accessible to sdAbs. Nanobodies
have been developed against components of the blood
clotting cascade and against aggregation-prone proteins
implicated in amyloid diseases. An sdAb (AU/VWFa-
11) derived from an immunized llama speciWcally
recognizes the activated form of von Willebrand factor
(vWF), a key component of the blood-clotting cascade
that mediates the tethering of platelets to the vascular
endothelial wall [50]. This sdAb proved useful for deter-
mining the levels of activated vWF in serum samples,
although it did not block the interaction between vWF
and its cognate integrin GpIba on the endothelial cells.
Another vWF-speciWc sdAb has recently completed
phase Ib clinical trial as an anti-thrombotic reagent,
showing dose dependent essentially complete inhibition
of vWF for a duration of 4 to 18 h for single dose appli-
cations and up to 24 h in multi-dose applications (http://
www.Ablynx.com).
Amyloidosis is a group of diseases caused by unusual
aggregation of proteins into amyloid Wbrils. The extra-
cellular accumulation of amyloid Ab peptide in insolu-
ble aggregates is associated with Alzheimer’s disease.
The use of speciWc antibodies for inhibiting Wbril
formation seems a promising therapeutic strategy [51].
An sdAb (cAb-HuL6) derived from a dromedary immu-
nized with wild type human lysozyme [52] inhibited the
in vitro aggregation of the amyloidogenic D67H variant
of lysozyme [12]. An Ab-speciWc VHH (V31-1) isolated
from an Ab-peptide-immunized alpaca, was shown to
preferentially bind to the oligomeric form of Ab. More-
over, this VHH inhibited Wbril formation and protected
neurons in vitro from Ab-induced neurotoxicity [53].
A conformation sensitive VHH (B10), selected from a
fully synthetic camelid library recognizes an epitope
common to diVerent amyloid Wbrils derived from
Ab peptide, Ig light chains, and serum amyloid protein
[54].
sdAbs directed against human serum albumin and
IgG, isolated from immune llama libraries, have been
shown to be useful for the bulk depletion of these pro-
teins from serum. Removal of immunoglobulins can
have therapeutic beneWt, for patients with high titers of
circulating autoantibodies, e.g., Goodpasture syndrome
and systemic lupus erythematosus (SLE) [55]. sdAb-
based aYnity-columns showed superior performance to
conventional protein A columns. sdAbs directed against
human and mouse serum albumin were shown to
increase the in vivo half-life of bispeciWc sdAb reagents
(Fig. 7e).
Targeting intracellular proteins with sdAbs—intrabodies, 
translocation peptides, and CDR3 peptide mimetics
The cell membrane is impermeable to proteins and, there-
fore, intracellular antigens are inaccessible to secreted
antibodies. Two experimental strategies have been pursued
to allow access of sdAbs to intracellular targets: the fusion
of sdAbs to peptides mediating translocation across the
cell membrane and transfection of cells with cDNA con-
structs encoding intracellular sdAbs. Several natural pro-
teins are equipped with specialized domains that mediate
membrane translocation. In some cases, transplantation of
such a translocation domain (td) onto another protein has
yielded constructs capable of membrane translocation,
albeit with highly variable eYciencies. Such td-fusion pro-
teins were constructed of a conventional single-chain vari-
able fragment (scFv) against the Bcl-2 anti-apoptotic
protein [56] and against the c-myc oncogene [57]. Very
high concentrations of these scFv-td fusion proteins had to
be added to cells to yield detectable pro-apoptotic eVects on
Bcl-2 or anti-proliferative eVects on c-myc. The require-
ments for protein translocation across the cell membrane
are poorly understood, but it is likely to involve retrograde
transport to an internal compartment, unfolding of the pro-
tein, translocation through a channel, and refolding in the
cytosol. It is conceivable that the presence of intrachain
disulWde bonds could hamper the unfolding and transloca-
tion steps and that replacement of the canonical cysteine
pair in the Ig-domain (Fig. 2) might improve translocation
eYciency of sdAbs.
The alternative strategy involves transfection of cells
and co-expression of the sdAb in the same cellular com-
partment as the target protein. sdAbs appear particularly
suited for this strategy as they can readily fold in diVerent
environments, including the cytosol, nucleus, and chloro-
plasts. Cell death induced by oxidative stress is involved
in pathologies of post-mitotic tissues, such as brain and
heart. Bax, a 24 kD protein of the Bcl-2 family, is
involved in the early phase of apoptosis and has been
implicated in neuronal death in ischemia. SpeciWc Bax
inhibitors hold promise as therapeutic tools for neurode-
generative disorders. Bax-speciWc sdAbs isolated from a
naïve llama library were shown to inhibit Bax induced
permeabilization of isolated mitochondria. Cell lines sta-
bly transfected with expression constructs for cytosolic
anti-Bax sdAbs were found to be resistant to oxidative
stress and showed signiWcantly reduced H2O2-induced
cytotoxicity [18].
Hypoxia triggers a transcriptional response, largely med-
iated by hypoxia-inducible factor-1alpha (HIF-1a) which
regulates the metabolic adaptation to reduced oxygen lev-
els. This metabolic adaptation allows tumor cells to thrive123
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ciWc sdAbs selected from a non-immune llama phage
display library were shown to be useful for diagnostic
purposes and for immunoprecipitation of HIF-1a. These
sdAbs are currently being studied for possible functional
modulation of HIF-1a function when expressed as intra-
bodies [58, 59].
Overexpression and/or trinucleotide repeat expansion in
the coding region of poly-A-binding protein 1 (PABN1)
can result in Wbril-like aggregation of PABN1 in the nuclei
of skeletal muscle cells, resulting in oculopharyngeal mus-
cular dystrophy (OPMD). A PABN1-speciWc sdAb was
selected from a non-immune llama library and fused
in-frame to a nuclear localization signal and green Xuorescent
protein [60]. Transfection of this construct into HeLa cells
conWrmed successful expression and tagging to the nucleus.
The construct was found to completely block aggregation
of co-expressed PABN1 and was even capable of clearing
already existing aggregates when transfected after PABN1.
In a Drosophila model of OPMD, expression of a PABN1-
speciWc intrabody strongly suppressed muscle degenera-
tion, leading to nearly complete rescue.
These Wndings underscore the potential of using sdAbs
for targeting intracellular as well as extracellular proteins.
A transfection-based expression strategy seems, in princi-
ple, applicable for transgenic animals and plants, as well as
in therapeutic settings, where cells transfected in vitro are
reapplied to the patient. Direct in vivo transfection has been
achieved for skin cells using ballistic DNA-immunization
and for the liver using hydrodynamic transfection by intra-
venous bolus injections of DNA in a large volume. In gen-
eral, however, in vivo transfection eYciencies are low. The
unusually long CDR3 of many camelid and shark antibod-
ies could potentially open the possibility of creating syn-
thetic peptide mimetics [61]. In a recent proof-of-principle
study, a peptide derived from the CDR3 of the lysozyme
blocking camel Ab cabLys3 (Fig. 3b) was shown to block
lysozyme activity. However, much higher concentrations of
this “peptibody” were required for inhibiting lysozyme than
of the parental VHH [62]. Nevertheless, it is possible that
synthetic peptibodies can be delivered more eYciently to
the cytosol than larger sdAbs.
Molecular assembly vaccines
The higher immunogenicity of repetitive proteins could
potentially be exploited also for increasing vaccine
eYciency. Lumazine synthase from Brucella abortus
spontaneously assembles into pentamers and decamers
and shows very high immunogenicity even during pri-
mary immunizations [63]. In our own labs, we have
raised sdAbs speciWc for lumazine synthase as tools to
interfere with Xavin biosynthesis in these pathogenic
bacteria. These sdAbs might also be useful for convert-
ing a monomeric antigen into a multimeric format by
providing a “piggyback” link to lumazine synthase, e.g.,
following cloning and recombinant production of an
sdAb-antigen fusion protein (Fig. 7i). We hypothesize
that the antigen’s immunogenicity will be much higher
in such a molecular assembly vaccine than in its original
monomeric format.
sdAbs as tools for molecular mimicry
Antibodies directed against the antigen-binding paratope
(idiotype) of another antibody are called anti-idiotypic anti-
bodies (anti-Id Abs) (Fig. 7j). Such anti-Id Abs compete
with the antigen for binding to the parental Ab and are
thought to share partially or completely the reactive surface
with the combining site, thus mimicking the structure of the
antigen. In a proof-of-principle study, two sdAbs were
selected from a llama immunized with a DNA-speciWc
monoclonal antibody (ED84) [64]. These sdAbs were
found to compete with a double-stranded DNA oligonu-
cleotide for binding to ED84 and thus bear a functional
mimicry of the DNA. In a similar approach anti-idiotypic
VNARs were selected from a semi-synthetic phage display
library against the idiotype of a monoclonal antibody spe-
ciWc for a linear tripeptide epitope in the Plasmodium falci-
parum apical membrane protein antigen-1 (AMA-1). These
VNARs showed enhanced aYnity compared to the parental
antigen [65].
Single domain antibodies in infection
Antibodies have a longstanding history as therapeutic
agents against toxins and pathogens. The Wrst Nobel Prize
in Medicine was awarded in 1901 to Emil von Behring for
his discovery of passive immune therapy as a cure for diph-
theria, a devastating epidemic disease in those days. The
molecular structure of antibodies, the eVective agent in the
diphtheria antiserum that von Behring obtained from
immunized horses, was solved only half a century later.
Today, another half century later, we have the tools for
cloning and reformatting antibodies from diVerent animals
and even for assembling antibodies semi-synthetically.
sdAbs, in particular, hold great promise to fulWll Paul Ehr-
lich’s vision of “magic bullets” for combating toxins and
pathogens [66, 67].
Targeting protein toxins and poisons with sdAbs
Some of the most potent toxins found in nature are
enzymes, including numerous proteins secreted by bacte-
ria and the venomous organs of snakes and scorpions.123
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llama phage display libraries (Table 2). Like murine
ART2.2, the SpvB Salmonella toxin is an ADP-ribosyl-
transferase that transfers ADP-ribose from NAD onto spe-
ciWc amino acid side chains of proteins [26, 31] (Fig. 8c).
Upon translocation into the cytosol of animal cells, SpvB
blocks cytoskeletal functions by ADP-ribosylating actin
and thereby blocking its polymerization. From an SpvB-
immunized llama, we have isolated SpvB-blocking sdAbs
that block SpvB enzymatic activity at a 1:1 molar ratio.
When expressed as intrabodies in transfected cells, these
nanobodies eVectively block SpvB-mediated disruption of
the cell cytoskeleton (Fig. 7h). Several other important
human pathogens, including V. cholera, B. pertussis, and
S. enterica, which induce disease by secreting toxin ARTs
[68] might similarly be suitable for targeting by enzyme-
blocking sdAbs.
Bacterial toxin-speciWc sdAbs have been successfully
isolated from naïve llama and naïve shark libraries,
including sdAbs speciWc for cholera toxin, staphylococcal
Table 2 Applications of sdAbs in infection
Target Application Source of sdAb Reference
Toxins
Salmonella SpvB toxin Neutralization Immune llama Alzogaray et al. (unpublished)
Cholera toxin, 
staphylococcus 
enterotoxin A, 
ricin, botulinum 
neurotoxin A
Biosensor Non-immune 
llama and 
non-immune 
shark
[69–71, 119]
LPS Depletion of endotoxin Non-immune llama [72]
Scorpion toxin Neutralization Immune camel 
and dromedary
[74, 77]
Scorpion/conus toxins Neutralization Immune shark Licea et al. (unpublished)
Alpha-cobrotoxin Antivenom development Non-immune llama [76]
Mycotoxin Detecting toxin contamination Immune llama [78]
Viruses
HIV env Neutralization Immune llama [84]
Rotavirus, gp6 Absorption of virus on lactobacillus Immune llama [17, 85, 120]
FMDV Neutralization Immune llama [86, 87]
Hepatitis B Blocking virus secretion Immune llama [20]
Lactococcus 
phage receptor 
binding protein
Protect milk fermentation Immune llama [88, 89]
Porcine retrovirus Neutralize endogenous 
retrovirus in 
transgenic pigs
Immune llama [91]
Marburg virus Biosensor/diagnosis Non-immune llama [92]
Bacteria
Streptococcus mutans Reduce dental caries Immune llama [94, 95]
E. coli F4 Wmbriae Treat pig diarrhea Immune llama [93, 121]
EspI:EpsJ pseudopilin Chaperone assisted crystallography Immune llama [97]
GspD secretin Chaperone assisted crystallography Immune llama [96]
b-lactamase Antibiotic enhancement Immune dromedary [52, 99]
Parasites
Variable surface 
glycoprotein 
(oligomannose)
Trypanosome drug delivery Immune dromedary [100, 101]
Trans-sialidase Trypanosomiasis diagnosis Immune llama [103]
Trypanosomes Infectome tools Immune dromedary [102]
AMA1 Malaria diagnosis Immune shark [122]
Taenia solium Tapeworm diagnosis Immune dromedary [104]123
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likely that many of these sdAbs possess only low aYnities
and their neutralization capacities have not been reported.
Notwithstanding, some have been shown useful for
diagnostic purposes, e.g., upon conversion to a multivalent
format by the attachment to beads. These sdAbs, thus, hold
promise for biosensor applications.
Endotoxin, i.e., lipopolysaccharide (LPS), released from
the outer membrane of gram-negative bacteria into the
blood circulation after infection can mediate severe septic
shock. LPS-speciWc sdAbs, selected from a non-immune
llama VHH phage display library, eVectively removed LPS
from serum and other aqueous solutions [72].
Venom of snakes, scorpions, spiders, and frogs represent
signiWcant threats to human health in many countries. Intra-
venous administration of conventional IgG or Fab frag-
ments prepared from immunized horses or sheep can
provide alleviation for some cases of systemic envenoming
and recent studies indicate that corresponding hcAbs pre-
pared from immunized camels and llamas are similarly or
even more eVective [73–75]. An sdAb against alpha cobra
toxin was derived from a naïve llama phage display library
and engineered into a pentameric format by genetic fusion
to the non-toxic B-subunit of verotoxin, yielding a reagent
with higher avidity and neutralization capacity [76]. An
sdAb directed against scorpion toxin (NbAahI922) derived
from an immunized dromedary showed potent neutralizing
capacity already in a monovalent format which was
enhanced further upon conversion into a bivalent heavy-
chain format by genetic fusion to the Fc region of human
IgG1 (Fig. 7f) [77].
Targeting small molecule toxins and other haptens 
with sdAbs
Fungi secrete small chemical compounds that can be
toxic to animal cells. Recently, an sdAb (NAT-267) was
developed from an immunized llama against BSA-conju-
gated Deoxynivalenol (300 Da), a mycotoxin produced
by common grain molds [78]. The high aYnity of this
sdAb paves way for developing low-cost toxin detection
systems and potentially also for immunomodulation of
Deoxynivalenol’s cytotoxic eVects. Other haptens have
been targeted by sdAbs, including red azo dyes (728 Da)
found in red wine (with the potential use of targeting
enzymes to stains during washing) [79], caVeine (with
the potential use of detecting caVeine in beverages) [80],
the explosive TNT (biosensor) [81], and the chemothera-
peutic agent methotrexate (MTX, 454 Da) [82]. Anti-
hapten sdAbs have potential in cancer therapy, for e.g.,
in a bi-speciWc format to help target radiolabeled hap-
tens to tumors for imaging and radioimmunotherapy
[83].
Targeting viruses with sdAbs
Viruses often use “hidden” epitopes on the capsid or enve-
lope, e.g., deep invaginations or canyons, for docking onto
receptors on host cells. Such epitopes are hidden from the
large and typically Xat antigen-binding sites of conven-
tional antibodies. Moreover, these epitopes are often well
conserved between viruses that use the same receptor while
more protruded regions of the capsid/envelope change rap-
idly, helping the virus to escape from immune attack. Anal-
ogous to the active site crevice of enzymes, these canyons
on the viral surface are usually inaccessible to conventional
antibodies, but constitute preferential targets for single-
chain antibodies from camelids and sharks. Numerous
viruses are being targeted by sdAbs, among these HIV, for
which crosstype-speciWc HIV-neutralizing sdAbs were
recently derived from an immunized llama [84].
Several groups have succeeded in raising sdAbs directed
against rotavirus, the causative agent of severe childhood
diarrhea. Immunization of a llama with a more internally
located capsid protein of rotavirus yielded sdAbs that rec-
ognize and neutralize several diVerent strains of rotavirus
[85]. In a mouse model, oral application of these sdAbs
provided signiWcant amelioration of diarrhea. In an elegant
approach to increase the local dose of rotavirus-absorbing
sdAbs, a rotavirus-speciWc sdAb derived from an immu-
nized camel was cloned in-frame with a lactobacillus cell
surface protease into a lactobacillus expression vector [17].
Transformation yielded recombinant versions of this com-
mensal gut bacterium that express a high density of
rotavirus-speciWc sdAbs on the cell surface (dubbed lacto-
bodies) (Fig. 7g). Feeding of the recombinant lactobacillus
also provided signiWcant protection from rotavirus-mediated
disease.
Foot and mouth disease virus (FMDV) neutralizing
sdAbs were isolated from a llama immunized with a crude
extract of FMDV-infected BHK cells [86]. The in vivo
half-life of these sdAbs was enhanced by genetic fusion to a
second VHH speciWc for pig IgG. Intramuscular adminis-
tration of these bispeciWc sdAbs signiWcantly reduced vire-
mia in subsequently infected piglets, but did not prevent
transmission of FMDV [87]. Virus-neutralizing sdAbs have
also been developed for industrial applications, e.g., for the
neutralization of phages that infect lactobacilli and thereby
present a signiWcant threat in the milk and cheese industry
[88–90].
sdAbs have been generated and applied successfully also
against intracellular viral proteins. Porcine endogenous ret-
roviruses (PERV) reside within the pig genome and are
capable of transfecting human cells in vitro, thereby pre-
senting a potential hazard for xenotransplantation. An
sdAb, isolated from a llama immunized with the 60 kD Gag
protein of porcine endogenous retrovirus [91] and123
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of virus particles. Transgenic expression of such sdAbs
could contribute to solving safety problems associated with
PERVs. Similarly, an sdAb derived from a llama immu-
nized with hepatitis B virus particles was converted into a
format targeted to the lumen of the endoplasmic reticulum
(ER) by fusion to the KDEL ER-retention signal. Cells co-
transfected with expression constructs for this sdAb reagent
and hepatitis B showed enhanced intracellular retention and
correspondingly diminished secretion of hepatitis B parti-
cles. In mouse models, the rapid intravenous bolus injection
of an expression vector for the hepatitis-speciWc sdAb in a
large volume of buVer resulted in eYcient hydrodynamic
transfection of liver cells and a therapeutic beneWt [20].
Four sdAbs were selected from a non-immune llama
library by panning against immobilized Marburg virus [92].
Even though these sdAbs from a naïve library displayed
only low aYnities, a sensitive diagnostic assay system
could be developed by converting the nucleoprotein-spe-
ciWc sdAbs into multivalent formats. Capture of the virus
was achieved by simple immobilization of the sdAbs on the
wells of an ELISA plate. Detection was achieved upon
genetic fusion to bacterial alkaline phosphatase which
forms homo-dimers, thus yielding a bivalent enzyme-linked
detection reagent. The assay allows detection of three Mar-
burg virus variants without cross reactivity to the four
Ebola virus species.
Targeting pathogenic bacteria with sdAbs
Single domain antibodies have also been raised against bac-
terial surface proteins with the goals of blocking attachment
of bacteria to host cells and/or for more eVective delivery of
pro-drugs. A VHH (K609) against E. coli F4 Wmbriae,
applied at high doses, reduced E. coli induced diarrhea in
piglets. However, when applied orally, a large portion of
this sdAb was found to be proteolytically degraded in the
upper gastrointestinal tract. Proteolytic degradation is med-
iated by pepsin in the stomach and by trypsin and chymo-
trypsin in the duodenum [93]. Using a DNA-shuZing
strategy involving the random recombination of gene seg-
ments obtained from VHH K609 and two other F4-speciWc
VHHs, following DNA fragmentation and PCR ampliWca-
tion, a variant VHH (K922) was selected that exhibited
>100-fold increase in resistance to in vitro degradation by
gastric and jejunal Xuid.
Streptococcus mutans, the main cause of dental caries,
achieves virulence in part via its ability to adhere to and to
accumulate on tooth surfaces. An sdAb (S36-VHH) was
developed from a llama immunized with a mixture of dis-
rupted and intact S. mutans and genetically fused to fungal
glucose oxidase, a homo-dimeric 150 kD enzyme that pro-
duces hydrogen peroxide (H2O2) in the presence of glucose
and oxygen. The fusion protein was readily produced in
yeast [94]. In a rat model of strong cariogenic challenge,
daily application of the sdAb monomer as well as the VHH-
glucose oxidase fusion protein resulted in a reduced level of
bacterial recovery 21 days after infection, albeit not at a sta-
tistically signiWcant level due to large variation in bacterial
recovery [95].
sdAbs have also been used successfully to improve the
probability of obtaining crystals for proteins that are diY-
cult to crystallize. An sdAb can assist the crystallization
process by stabilizing the protein of interest and/or by cre-
ating additional crystal contact surface. VHHs isolated
from immunized llamas were used to assist the crystalliza-
tion of major components of the type 2 secretion system of
enteropathogenic E. coli and Vibrio. This 11 component
extracellular protein secretion system is used for secretion
of cholera toxin and heat labile enterotoxin [96, 97]. Simi-
larly, the phage P2 receptor-binding protein was success-
fully co-crystallized with an sdAb [98].
Many bacteria secrete enzymes that inactivate antibiotics
as an eYcient escape mechanism from antibiotic therapy.
Enzyme-blocking sdAbs were generated from immunized
dromedaries that eVectively block b-lactamases which cata-
lyze the hydrolysis of b-lactam antibiotics [99] with the
potential utility of improving antibiotic therapies.
Targeting parasites with sdAbs
Single domain antibodies are also being developed as anti-
parasite reagents. Trypanosomes are coated with variable
surface glycoproteins (VSGs) and evade host immune
responses by changing the VSGs that cover the entire mem-
brane. Owing to their smaller size, sdAbs might better pen-
etrate the VSG coat to gain access to conserved epitopes
that are inaccessible for conventional antibodies. An sdAb
(NbAn33) recognizing an oligomannose cryptic epitope on
trypanosomes was isolated from a dromedary immunized
with puriWed VSG [100]. In contrast to conventional anti-
bodies and lectins, this sdAb was able to penetrate the
dense VSG coat. A Xuorochrome-conjugate of this sdAb
allowed the direct sensitive detection of parasites in blood
smears. Immunotoxins were generated by genetically fus-
ing this sdAb (An33) to either b-lactamase or a truncated
version of the pore forming human serum protein apolipo-
protein L-I (Fig. 7c). Fusion to b-lactamase, which can con-
vert a cephalosporin-based prodrug into the potent toxic
phenylenediamine mustard (PDM), yielded a conjugate
with both, retained capacity to bind to trypanosomes and
retained enzyme activity. Sub-lethal doses of the pro-drug
proved highly toxic to conjugate treated parasites. Genetic
fusion to a truncated form of human apolipoprotein L-I
yielded an immunotoxin with lytic activity against a range
of diVerent trypanosomes [101]. In a mouse model the123
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eVects on acute and chronic infections with trypanosomes.
Further sdAbs directed against VSG and other trypanosome
proteins were selected from an immune library obtained
from a dromedary infected with live trypanosomes [102].
We have also obtained and characterized sdAbs directed
against trans-sialidase from Trypanosoma cruzi [103]. Even
though these sdAbs are unable to interfere with the crucial
role of trans-sialidase in cell entry of the parasite, they
served as a tool to unmask a novel strategy of T. cruzi to
evade the host immune system.
The larval form of the pork tapeworm Taenia solium is
the cause of cysticercosis, the most common parasitic
infection of the central nervous system and a major cause of
epilepsy in developing countries. Immunization of two
dromedaries with T. solium extracts yielded an sdAb
(Nbsol52) recognizing the 14 kD diagnostic glycoprotein
Ts14 [104]. This sdAb showed subnanomolar aYnity for
Ts14 and was found capable of capturing antigen present in
the serum of infected pigs. Further studies are required to
assess the potential therapeutic use of such sdAbs in cysti-
cercosis. Malassezia furfur is a fungus implicated in dan-
druV. sdAbs speciWc for a cell wall protein of M. furfur
were derived from an immunized llama [105]. Some of
these sdAbs were found to be resistant to detergents in
shampoo and may provide a possible antifungal additive to
shampoos.
Conclusions and perspectives
Approximately 15 years have passed since the serendipi-
tous discovery of the peculiar hcAbs in camels [2], fol-
lowed by the elucidation of the similar, heavy-chain-only
structure of shark new antigen receptors [106]. The remark-
able proof-of-principle studies published since then point to
a tremendous diagnostic and therapeutic potential of single
domain antibody reagents derived from these hcAbs.
Numerous sdAbs have already proven useful for basic
research and as improved diagnostic and biosensor tools.
In vivo studies have underscored the favorable biodistribu-
tion of sdAbs, including deep penetration into dense tissues
and rapid elimination via the kidney. These features make
sdAbs particularly amenable for imaging of tumors and for
the delivery of cytotoxic agents. sdAbs should also prove
useful for neutralizing soluble extracellular proteins includ-
ing toxins, cytokines, and blood clotting components. The
capacity of sdAbs to block leukocyte ecto-enzymes indi-
cates their potential utility as anti-inXammatory and
immune modulating agents.
Notwithstanding, a number of obstacles still have to be
surmounted before widespread clinical application of
sdAbs becomes possible. A major concern for repeated and/
or long-term clinical use is the potential immunogenicity of
sdAb reagents. While the systemic application of small
monovalent sdAbs seems to induce little, if any, neutraliz-
ing antibody responses, protein immunogenicity generally
increases with size and complexity. This will likely pertain
also for the fusion constructs illustrated in Fig. 7. Enhanced
immunogenicity, of course, is desired in case of vaccines,
but not for therapeutic applications. Recently, a strategy to
humanize camelid sdAb was described in which the surface
of a camel sdAb was reshaped by mutating 12 out of the 14
surface-exposed residues in which camel sdAbs diVer from
human VH domains to the corresponding human residue
[107]. It remains to be determined whether these human-
ized VHH display lower immunogenicity than the camelid
sdAb. Immunogenicity is a particular concern for intrave-
nous and other systemic injections, but may be less prob-
lematic for other routes of application, in particular
gastrointestinal and intraocular injections. Moreover, single
injections, such as for the treatment of acute toxin expo-
sure, are less immunogenic than the repeated applications
required for the treatment of chronic inXammatory diseases.
For intracellular targets, more eYcient delivery tools
will need to be developed for sdAbs to reach the cytosol
and other intracellular compartments. Transfection-medi-
ated expression of intracellular sdAbs appears to be a feasi-
ble strategy for cell/gene therapy regiments and for
transgenic plants and animals. For humans, however,
in vivo transfection so far seems feasible only for accessi-
ble tissues, such as skin and possibly the liver. Considering
that antigen-binding of many camelid and shark sdAbs is
mediated in large part by their long CDR3, it may be possi-
ble in some cases to develop peptide-mimetics of the anti-
gen-binding principle [61].
Presently, the immunization of llamas and dromedaries
is cumbersome and costly in comparison to immunization
of smaller animals. Transgenic mice expressing camelid
antibodies, analogous to the transgenic mice expressing
human antibodies [22], could provide more economic
sources of sdAbs. A recent study provided a Wrst proof-of-
principle that single-chain antibodies, indeed, can be cor-
rectly assembled and expressed by B-cells of transgenic
mice carrying a mini-Ig construct encoding a dromedary
VHH and the Fc-domain of human IgG1 [108, 109].
Assuming that progress will continue at the present pace,
it is likely that the future repertoire of researchers and clini-
cians will include a battery of sdAb reagents directed
against cytokines, ecto-enzymes, tumor antigens, toxins,
and microbes.
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